Please assess the completion status of the following clinical trial:

Trial Title: Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient at least 18 years of age and of any race or ethnicity who is undergoing Descemet stripping only for Fuchs dystrophy~* Is able and willing to administer eye drops~* Is able to comprehend and has signed the Informed Consent form.~Exclusion Criteria:~* Active intraocular inflammation~* Corneal ulceration, keratitis, or conjunctivitis~* Known sensitivity to any of the ingredients in the study medications~* Abnormal eyelid function~* History of herpetic keratitis~* History of non-compliance with using prescribed medication~* Current or planned pregnancy within the study duration~* Concurrent involvement or participation in another randomized clinical trial within 30 days prior to enrollment in this study~* Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation which in the investigator's opinion may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil (Type: EXPERIMENTAL): Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner
- Placebo (Type: PLACEBO_COMPARATOR): Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.

Based on this trial design, predict the completion outcome and termination type (if applicable).